1. Record Nr. UNINA9910555117403321

Autore	Ortolani C (Claudio)
Titolo	Flow cytometry of hematological malignancies / / Claudio Ortolani
Pubbl/distr/stampa	Hoboken, New Jersey ; ; Chichester, West Sussex, England : , : Wiley Blackwell, , [2021] ©2021
ISBN	1-119-61130-X 1-119-61127-X 1-119-61128-8
Edizione	[Second edition.]
Descrizione fisica	1 online resource (467 pages)
Disciplina	574.87028
Soggetti	Flow cytometry Hematological oncology Flow cytometry - Methodology Electronic books.
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di bibliografia	Includes bibliographical references (pages 301-428) and index.
Nota di contenuto	Cover -- Title Page -- Copyright Page -- Contents -- Foreword to the Second Edition -- Foreword to the First Edition -- Foreword to the First Edition -- Preface to the Second Edition -- Preface to the First Edition -- Abbreviations -- Chapter 1 Antigens -- CD1 Antigens -- CD2 Antigen -- CD3 Antigen -- CD4 Antigen -- CD5 Antigen -- CD7 Antigen -- CD8 Antigen -- CD10 Antigen -- CD11b Antigen -- CD11c Antigen -- CD13 Antigen -- CD14 Antigen -- CD15 Antigen -- CD16 Antigen -- CD19 Antigen -- CD20 Antigen -- CD22 Antigen -- CD23 Antigen -- CD24 Antigen -- CD25 Antigen -- CD26 Antigen -- CD27 Antigen -- CD28 Antigen -- CD30 Antigen -- CD33 Antigen -- CD34 Antigen -- CD38 Antigen -- CD43 Antigen -- CD45 Antigen -- CD45 Isoforms -- CD49 Antigens -- CD56 Antigen -- CD57 Antigen -- CD61 Antigen -- CD62L Antigen -- CD64 Antigen -- CD65 Antigen -- CD66c Antigen -- CD71 Antigen -- CD79 Antigen -- CD81 Antigen -- CD103 Antigen -- CD117 Antigen -- CD123 Antigen -- CD138 Antigen -- CD200 Antigen -- CD305 Antigen -- CD307 (IRTA) Family -- CD371 Antigen -- BCL-2 Protein -- Chemokines and Chemokine

Receptors -- Chemokines -- Chemokine Receptors -- CRLF2 Antigen -- Cytotoxic Proteins -- HLA-DR Antigen -- Immunoglobulins -- KIRs, CD158 Isoforms -- Myeloperoxidase -- NG2 Antigen -- PCA-1 Antigen -- ROR1 Antigen -- SLAM Molecules and SLAM-Associated Protein -- SOX11 -- T-Cell Receptor (TCR) -- Terminal Deoxy-Nucleotidyl Transferase -- Toll-Like Receptors -- VS38 Antigen -- ZAP-70 Protein -- Chapter 2 Diseases -- Myeloproliferative neoplasms -- Chronic myeloid leukemia (CML) -- Myeloproliferative neoplasms other than CML -- Chronic neutrophilic leukemia (CNL) -- Polycythemia vera (PV) -- Primary myelofibrosis (PMF) -- Essential thrombocythemia (ET) -- Chronic eosinophilic leukemia (CEL) -- Mastocytosis -- Acute mast-cell leukemia (AMCL).
Chronic mast-cell leukemia (CMCL) -- Myelomastocytic leukemia (MML) -- Myelodysplastic/myeloproliferative neoplasms -- Chronic myelomonocytic leukemia (CMML) -- Other myelodysplastic/myeloproliferative neoplasms and related conditions -- Juvenile myelomonocytic leukemia (JMML) -- Atypical CML bcr/abl negative (ACML) -- RAS-associated autoimmune leukoproliferative disorder (RALD) -- Myelodysplastic syndromes -- Myeloid neoplasms with germline predisposition -- Acute myeloid leukemias -- AMLs with recurrent genetic anomalies -- AMLs with chromosomal anomalies -- AMLs with gene mutations -- Relationships between genotype and phenotype in cases of AML not recognized as separate entities in WHO 2017 -- AMLs with myelodysplasia-related changes (AML-MRC) -- AMLs not otherwise specified -- AML with minimal differentiation -- AML without maturation -- AML with maturation -- Acute myelomonocytic leukemia (AMMoL) -- Acute monoblastic and monocytic leukemia (AMoL) -- Pure erythroid leukemia (PEL) -- Acute megakaryoblastic leukemia (AMKL) -- Acute basophilic leukemia (ABL) -- Myeloid proliferations associated with Down syndrome -- Transient abnormal myelopoiesis (TAM) -- AMLs in patients with Down syndrome -- Blastic plasmacytoid dendritic cell neoplasm (BPDCN/PDCL) -- Acute leukemias with ambiguous lineage attribution (ALAL) -- Acute undifferentiated leukemias (AUL) -- Mixed phenotype acute leukemias (MPAL) -- Neoplastic diseases of B and T lymphatic precursors -- B lymphoblastic leukemia/lymphoma, not otherwise specified (B-ALL/LBLnos) -- B lymphoblastic leukemia/lymphoma with recurrent genetic anomalies -- Relationships between genotype and phenotype in cases of B-ALL not recognized as separate entities in WHO 2017 -- T lymphoblastic leukemia/lymphoma (T-ALL/LBL) -- Early T-cell precursor lymphoblastic leukemia (ETP-ALL).
NK lymphoblastic leukemia/lymphoma (NK-ALL/LBL) -- Neoplastic diseases of mature B cells -- Chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL) -- Familial B-CLL -- Richter syndrome -- Monoclonal B-cell lymphocytosis (MBL) -- CLL-like monoclonal B lymphocytosis -- Non-CLL-like monoclonal B lymphocytosis -- B-cell prolymphocytic leukemia (B-PLL) -- Lymphoplasmacytic lymphoma (LPL) -- Heavy chain disease (HCD) -- heavy chain disease -- heavy chain disease -- Hairy cell leukemia (HCL) -- Hairy cell leukemia, variant (HCL-v) -- Hairy cell leukemia, Japanese variant (HCL-J) -- Splenic diffuse red pulp lymphoma (SDRPL) -- Marginal zone lymphomas (MZL) -- Nodal marginal zone lymphoma (NMZL) -- Splenic marginal zone lymphoma (SMZL) -- Extranodal marginal zone lymphoma (EMZL/MALToma) -- Clonal B-cell lymphocytosis with MZL-like phenotype (CBL-MZ) -- Follicular lymphoma (FCL) -- Testicular follicular lymphoma -- Duodenal type follicular lymphoma -- Pediatric type follicular lymphoma -- Primitive cutaneous follicular lymphoma (PCFL) -- Large B-cell lymphoma with

IRF4 rearrangement -- Mantle-cell lymphoma (MCL) -- Blastic mantle-cell lymphoma (BMCL) -- Leukemic non nodal mantle-cell lymphoma -- DLBCL not otherwise specified (DLBCLnos) -- CD5(+) diffuse large cell lymphoma (CD5(+) DLBCL) -- T-cell/histiocyte-rich B-cell lymphoma (THRLBCL) -- Primary DLBCL of the CNS (PCNSL) -- Primary cutaneous DLBCL, "leg type -- EBV(+) DLBCLnos -- DLBCL associated with chronic inflammation (PAL) -- Fibrin associated DLBCL -- Lymphomatoid granulomatosis (LYG) -- Primary mediastinal B-cell lymphoma (PMBCL) -- Intravascular large B-cell lymphoma (IVBCL) -- ALK-positive large cell lymphoma (ALK(+) LBCL) -- Plasmablastic lymphoma (PBL) -- Primary effusion lymphoma (PEL) -- HHV8-associated lymphoproliferative disorders -- HHV8-positive DLBCL. HHV8-positive germinotropic lymphoproliferative disorder -- Burkitt lymphoma (BL) -- Burkitt leukemia with immature phenotype -- Burkitt-like lymphoma with 11q aberrations -- High-grade B-cell lymphoma (HGBL) -- Plasma cell neoplasms -- Monoclonal gammopathies of undetermined significance (MGUS) -- Multiple myeloma (MM) -- Plasma cell leukemia (PCL) -- Neoplastic diseases of mature T and NK cells -- T-cell prolymphocytic leukemia (T-PLL) -- T-cell large granular lymphocytic leukemia (T-LGL) -- Chronic lymphoproliferative disorders of NK cells (CLPD-NK/CNKL) -- Aggressive NK-cell leukemia (ANKL) -- Adult T-cell leukemia/lymphoma (ATLL) -- Extranodal NK/T-cell lymphoma, "nasal type" (ENKTL) -- Intestinal T-cell lymphomas (ITCL) -- Enteropathy-associated T-cell lymphoma (EATCL) -- Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) -- Indolent gastro-intestinal T lymphoproliferative disorder (indolent GI T-LPD) -- Hepatosplenic T-cell lymphoma (HSTCL) -- Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) -- Mycosis fungoides (MF) -- Sezary syndrome (SS) -- Primary cutaneous CD30(+) lymphoproliferative disorders -- Lymphomatoid papulosis (LyP) -- Primary cutaneous anaplastic T-cell lymphoma (pcALCL) -- Primary cutaneous peripheral T-cell lymphoma (PTCL) -- Primary cutaneous TCRƒÁƒÂ(+) T-cell lymphoma (PCGD-TCL) -- Primary cutaneous CD8(+) aggressive epidermotropic cytotoxic T-cell lymphoma (PCAETL) -- Primary cutaneous acral CD8(+) T-cell lymphoma (PCATCL) -- Primary cutaneous lymphoma of the medium/small CD4(+) T cells (PCSM-TCL) -- Peripheral T-cell lymphoma, not otherwise specified (PTCLnos) -- Nodal lymphomas of follicular T-helper derivation -- Angioimmunoblastic T-cell lymphoma (AITL) -- Follicular T-cell lymphoma (FTCL) -- Nodal PTCL with follicular T-helper phenotype -- Anaplastic large cell lymphoma ALK(+) (ALCL ALK(+)).
Anaplastic large cell lymphoma ALK(-) (ALCL ALK(-)) -- Breast implant. associated anaplastic large cell lymphoma (biaALCL) -- Hodgkin lymphomas -- Classic Hodgkin lymphoma (CHL) -- Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) -- Neoplastic diseases of histiocytic and dendritic cells -- Histiocytic sarcoma (HS) -- Langerhans cell histiocytosis (LCH) -- Indeterminate dendritic cell tumor (IDCT) -- Interdigitating dendritic cell sarcoma (IDCS) -- Follicular dendritic cell sarcoma (FDCS) -- Erdheim.Chester disease (EDC) -- Chapter 3 Appendix -- Acute leukemias not recognized by the 2017 WHO classification -- Acute leukemia of myeloid/NK precursors (M/NK-AL) -- Acute leukemia of myeloid dendritic cells (MDCL) -- Acute leukemia of Langerhans cells -- Composite lymphomas -- Hypereosinophilic syndrome (HES), lymphocyte variant -- Indolent T lymphoblastic proliferations (iT]LBP) -- Polyclonal lymphocytoses of B lymphocytes -- Persistent polyclonal B]cell lymphocytosis (PPBL) -- Persistent polyclonal CD5(+) B]cell lymphocytosis -- Persistent